Advances

FDA approves expansion of Avastin in ovarian cancerFDA recently approved bevacizumab (Avastin, Genentech) for patients with platinum-sensitive recurrent epithelial ovarian (psOC), fallopian tube or primary peritoneal cancer.
New drug indication could net more than $1 billionFDA’s approval of a new indication for empagliflozin (Jardiance, Eli Lilly and Boehringer Ingelheim) could net the pharmaceutical manufacturers more than $1 billion.
FDA approves 2 injectable diabetes drugsTwo new diabetes drugs, both long-acting injectable insulin products, were simultaneously approved by FDA.
Ixazomib for multiple myelomaFDA approved ixazomib (Ninlaro, Takeda) in combination with lenalidomide and dexamethasone
FDA approves Epclusa (sofosbuvir/velpatasvir) for chronic hepatitis C infectionFDA approved EpclusaTM (sofosbuvir and velpatasvir, (SOF-VEL) for adults with chronic hepatitis C infection both with compensated cirrhosis or without cirrhosis as well as in combination with ribavirin for hepatitis C with decompensated cirrhosis.
Research looks at melanocyte role in tumor formationWhile melanocytes have strong mechanisms for repair, those in individuals with certain risk factors may carry impaired repair responses. Studies have begun to examine melanocytes in patients at risk for developing melanoma with the hope of developing strategies for preventing deadly tumors.

Poll

View Results